Roche up, Pfizer out - The Patent Asset Index™ for Alzheimer’s and Parkinson’s patents

Posted by Benjamin Hann on Oct 16, 2018 8:33:56 AM

 

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

Read More

Tags: Patent Asset Index, Patent Analysis, Patent Valuation


PatentSight is now part of LexisNexis® IP

Posted by Nils Omland on May 16, 2018 2:32:17 PM

You may have seen our recent press release but I wanted to personally express my excitement over the recent acquisition by LexisNexis® IP. We anticipate that as a result of this acquisition, we will be able to make significant enhancements to our product.

With added content, financial resources, and a broader customer base we will significantly accelerate our development. In particular, the advent of powerful self-learning algorithms often described as “artificial intelligence” is a great opportunity to reach the next breakthrough in patent analytics. We are thrilled to leverage our competence in high quality data and reliable science-based algorithms to continue leading the field with advanced tools that offer unique and reliable business insights.

Rest assured, many things you value about PatentSight will not change. PatentSight will continue under the leadership of myself and my team in the same offices in Bonn, Germany. All PatentSight employees will be retained and your current points of contact will not change. Our much-praised Consulting & Support Team will continue to serve you directly. The name of the product will change slightly to LexisNexis PatentSight.

We look forward to our continued relationship. Please contact me, Björn Ulmer or your main contact in the business development team if you have any additional questions.

Read More

Tags: Mergers and Acquisitions, Patent Valuation, Science, Technology, IP Data Quality, Patent Analysis, Innovation, Patent Asset Index


Broadcom may have to pay more for Qualcomm’s superior innovation based on analysis by PatentSight

Posted by Dan Lonkevich - Guest Blogger on Feb 22, 2018 3:39:33 PM

An analysis of the patent portfolios of Broadcom Ltd. (AVGO), Qualcomm Inc. 
(QCOM) and NXP Semiconductor (NXPI) by PatentSight GmbH, suggests that Qualcomm’s portfolio is rated highest among the three companies based on the Patent Asset Index (PAI)

The PAI is a scientifically developed and industry proven methodology to measure the 
innovative strength of an enterprise or an entire technology field. It is calculated at the level of a patent portfolio as the sum of the competitive impact scores of the individual patent families contained in this portfolio. The competitive impact in turn is calculated based on the technology relevance (citation-based indicator) and market coverage (patent protection around the globe, calculated based on the potential economic value of each country) of a patent family. Depending on the question to be addressed the Patent Asset Index can be calculated for a company as a whole, or just for patents belonging to specific business areas or technology fields: it then shows the strength of the company in those particular domains only.

Read More

Tags: Patent Analysis, Mergers and Acquisitions